ArticleLife (Basel, Switzerland)2026
Enhanced Imaging in Bladder Cancer: Fluorescence Cystoscopy and Molecular Diagnostics.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesBladder cancer remains one of the most frequently diagnosed malignancies worldwide and is characterized by high recurrence rates requiring long-term surveillance. Conventional white-light cystoscopy (WLC) remains the standard diagnostic method; however, it may fail to detect flat lesions such as carcinoma in situ or small papillary tumors. In recent years, enhanced imaging techniques, including fluorescence cystoscopy and autofluorescence-based systems, have been introduced to improve diagnostic accuracy. The aim of this study is to evaluate the usefulness of fluorescence-based diagnostic techniques and autofluorescence imaging supported by numerical color value (NCV) analysis in the detection and assessment of bladder lesions.
methodsThe study was conducted at the Center of Photodynamic Diagnostics and Therapy, Department of Internal Medicine, Angiology and Physical Medicine, Medical University of Silesia in Bytom. Bladder mucosa was assessed using the Onco-LIFE optical imaging system, which enables visualization under both white-light and autofluorescence conditions. The study included 30 patients diagnosed with non-muscle-invasive bladder cancer or suspected bladder lesions, who underwent cystoscopic evaluation using white-light cystoscopy and autofluorescence imaging. From this cohort, three representative cases were selected for detailed qualitative presentation to illustrate different pathological conditions of the bladder mucosa. In selected cases, photodynamic diagnosis (PDD) using intravesical administration of 5-aminolevulinic acid (ALA) was performed prior to cystoscopic examination. Autofluorescence signals were analyzed using red and green fluorescence channels, and tissue characteristics were evaluated using the numerical color value parameter.
resultsRepresentative cases of non-muscle-invasive bladder lesions were analyzed and compared using conventional white-light cystoscopy and autofluorescence imaging. The use of fluorescence-based imaging enabled improved visualization of suspicious mucosal changes compared with standard WLC. Differences in fluorescence patterns were observed between malignant lesions, inflammatory changes, and carcinoma in situ. NCV analysis allowed quantitative assessment of fluorescence signals and supported differentiation of pathological tissue from normal bladder mucosa.
conclusionsFluorescence cystoscopy and autofluorescence-based imaging systems represent valuable tools for improving the detection of bladder lesions during endoscopic examination. The integration of enhanced optical imaging techniques with quantitative fluorescence analysis may increase diagnostic sensitivity and support targeted biopsy and tumor resection. Continued technological development and clinical experience may further expand the role of fluorescence diagnostics in the early detection and management of bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.